Novo doubles down on next-gen weight loss therapy despite early setback
by
Contributor since / Followers
Contributor since / Followers
2 months ago
JHVEPhoto/iStock Editorial via Getty Images
With its Q4 2024 results on Wednesday, Novo Nordisk (NVO) announced a new Phase 3 trial to test its highly-anticipated weight loss therapy, CagriSema, after a December readout failed to meet investors’ lofty expectations for the next-gen candidate.
The new